

13th annual meeting

# NorPEN

Nordic PharmacoEpidemiological Network



November 11-12th 2021  
Karolinska Institutet, Stockholm

## Pre-conference course

### A general overview of G methods in relation to pharmacoepidemiology

Wednesday November 10th	
<b>Afternoon</b> <b>Exact time</b> <b>TBA</b> <b>4 hours</b>	<p><i>Online participation only</i></p> <p>G-methods is a class of methods for estimating the causal effects of time-varying treatment strategies in longitudinal studies where time-varying confounders may be affected by past treatment. G-methods specifically aim to estimate Robins's <i>g-formula</i>, a function of only measured study variables. Under assumptions that include no unmeasured confounding, the <i>g-formula</i> indexed by a particular time-varying treatment strategy equals the (counterfactual) outcome mean in the study population had all individuals adhered to that strategy. The <i>g-formula</i> is usually a high-dimensional function when the dimension of measured confounders is high and/or there are many follow-up times. Different <i>g-methods</i> (e.g. inverse probability weighting, parametric <i>g-computation</i>, targeted maximum likelihood estimation) constitute different estimation methods for this function of the longitudinal data.</p> <p>In this workshop, attendees will gain a greater understanding of the theory that motivates these methods for causal effects. This theory will cover various types of treatment rules, from simple <i>static deterministic</i> rules to more complex <i>dynamic stochastic</i> rules. Details of various estimation algorithms will be provided along with motivating examples</p> <p><b>Instructor: Jessica Young, PhD</b> <b>Assistant Professor and Biostatistician</b> <b>Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Department of Population Medicine, USA</b></p> <p><i>Dr Young's research focuses on the development and application of statistical methods for estimating policy and clinically relevant causal effects of time-varying treatment strategies on health outcomes in the face of complex time-varying confounding and selection bias, competing events and treatments that are challenging to measure.</i></p>

Funded by [SFO Epi: The Strategic Research Area in Epidemiology and Biostatistics](#), Karolinska Institutet

13th annual meeting

# NorPEN

Nordic PharmacoEpidemiological Network

November 11-12th 2021  
Karolinska Institutet, Stockholm

## Preliminary Program

August 2021

*Note: Break times to be updated to accommodate online format*

**Theme: Sustainability of Nordic Collaboration**

Thursday November 11th	
9:00-9:15	Welcome and Introduction
9:15-10:30	<b>Session 1-1: Sustainability - Overcoming challenges of data sharing in Nordic Collaborations</b> <ul style="list-style-type: none"><li>• <i>Nordic Common Data Models</i> Morten Andersen, University of Copenhagen, Denmark</li><li>• <i>Federated Analyses, data sharing rules and limitations</i> Rolf Gedeberg, Swedish Medical Products Agency, Sweden</li><li>• <i>Summary and Discussion</i> Moderator: Björn Wettermark, Uppsala University, Sweden</li></ul>
10:30-11:00	Break / Online mingle
11:00-12:00	<b>Session 1-2: Oral Presentations</b> Moderator: Carolyn Cesta, Karolinska Institutet, Sweden
12:00-13:00	Lunch break
13:00-13:30	<b>Session 1-3: PharmacoepiSLAMs</b> Moderator: Laura Pazzagli, Karolinska Institutet, Sweden
13:30-16:30	<b>Session 1-4: Observational effectiveness studies, pragmatic trials, and their value to regulatory decisions</b> <ul style="list-style-type: none"><li>• <i>Register randomized trials</i> Stefan James, Uppsala University, Sweden</li><li>• <i>Cluster trials</i> Gunilla Andrew Nielsen, Swedish Medical Products Agency, Sweden</li><li>• <i>Industry perspective</i> Claudia Cabrera, AstraZeneca, Sweden</li></ul> Coffee break <ul style="list-style-type: none"><li>• <i>Can observational comparative effectiveness studies be used for Health Technology Assessment?</i></li></ul>

	<p>TBA, The Dental and Pharmaceutical Benefits Agency, Sweden</p> <ul style="list-style-type: none"> <li>• <i>RCT DUPLICATE - emulating current trials</i> Sebastian Schneeweiss, Brigham and Women's Hospital, Division of Pharmacoepidemiology and Pharmacoeconomics, Harvard Medical School.</li> <li>• <i>Panel discussion with session speakers</i> Moderator: Björn Pasternak, Karolinska Institutet, Sweden</li> </ul>
--	---

<b>Friday November 12th</b>	
<b>8:45-10:00</b>	<p><b>Session 2-1: Sustainability – Upcoming Nordic Data Sources and Avenues for Access</b></p> <ul style="list-style-type: none"> <li>• <i>Natural language processing for prescription text</i> Zheng Chang, Karolinska Institutet, Sweden</li> <li>• <i>The new Danish Hospital Medication Register</i> Dorte Vesterholm Lind, Sundhedsdatastyrelsen, Denmark</li> <li>• <i>Changes to data request processing and delivery to researchers in the COVID19-era</i> Anna Bennet Bark, Swedish National Board of Health and Welfare, Sweden</li> <li>• <i>Discussion</i> Moderator: Rickard Ljung, Swedish Medical Products Agency, Sweden</li> </ul>
<b>10:00-10:30</b>	<p><b>Session 2-2: PharmacoepiSLAMs</b> Moderator: Zheng Chang, Karolinska Institutet, Sweden</p>
<b>10:30-11:00</b>	Break
<b>11:00-11:35</b>	<p><b>Session 2-3: Methods – An application of g-methods</b> Xiaojuan Li, Harvard Medical School and Harvard Pilgrim Health Care Institute, Department of Population Medicine, USA Moderator: Laura Pazzagli, Karolinska Institutet, Sweden</p>
<b>11:35-12:45</b>	<p><b>Session 2-4: Oral Presentations</b> Moderator: Karolina Andersson Sundell, AstraZeneca, Sweden</p>
<b>12:45-12:55</b>	<p><b>Past, Present &amp; Future of Nordic Pharmacoepidemiology Collaboration</b> Helle Kieler, Karolinska Institutet, Sweden</p>
<b>12:55-13:00</b>	Wrap up and announcing NorPEN 2022

